Loading...
Header Logo
Keywords
Last Name
Institution

BENIGNO VALDEZ

TitleAssociate Professor
InstitutionMD Anderson
DepartmentStem Cell Transplantation
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    R55CA068351     (VALDEZ, BENIGNO C)Sep 30, 1995 - Sep 29, 1998
    NIH/NCI
    AG-NOR PROTEINS USED FOR CANCER DIAGNOSIS
    Role: Principal Investigator

    R01DK052341     (VALDEZ, BENIGNO C)Sep 1, 1999 - Aug 31, 2005
    NIH/NIDDK
    AUTOANTIGEN RNA HELICASE II/GU
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Popat UR, Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Jones R, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Parmar S, Rezvani K, Qazilbash MH, Shah N, Srour SA, Shpall EJ, Champlin RE, Andersson BS. Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. Lancet Haematol. 2018 Nov; 5(11):e532-e542. PMID: 30389035.
      View in: PubMed
    2. Valdez BC, Tang X, Li Y, Murray D, Liu Y, Popat U, Champlin RE, Andersson BS. Epigenetic modification enhances the cytotoxicity of busulfan and4-hydroperoxycyclophosphamide in AML cells. Exp Hematol. 2018 11; 67:49-59.e1. PMID: 30102945.
      View in: PubMed
    3. Nieto Y, Thall PF, Ma J, Valdez BC, Ahmed S, Anderlini P, Popat U, Jones RB, Shpall EJ, Hosing C, Qazilbash M, Kebriaei P, Alousi A, Timmons M, Gulbis A, Myers A, Oki Y, Fanale M, Dabaja B, Pinnix C, Milgrom S, Champlin R, Andersson BS. Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2018 Aug; 24(8):1602-1609. PMID: 29501779.
      View in: PubMed
    4. Valdez BC, Li Y, Murray D, Liu Y, Nieto Y, Champlin RE, Andersson BS. Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells. Oncotarget. 2018 Jan 09; 9(3):3908-3921. PMID: 29423093.
      View in: PubMed
    5. Nieto Y, Valdez BC, Pingali SR, Bassett R, Delgado R, Nguyen J, Shah N, Popat U, Jones RB, Andersson BS, Gulbis A, Ahmed S, Bashir Q, Parmar S, Patel K, Myers A, Rondon G, Orlowski RZ, Champlin R, Qazilbash M. High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. Lancet Haematol. 2017 Jun; 4(6):e283-e292. PMID: 28522110.
      View in: PubMed
    6. Valdez BC, Hassan M, Andersson BS. Development of an assay for cellular efflux of pharmaceutically active agents and its relevance to understanding drug interactions. Exp Hematol. 2017 08; 52:65-71. PMID: 28479418.
      View in: PubMed
    7. Valdez BC, Li Y, Murray D, Liu Y, Nieto Y, Champlin RE, Andersson BS. The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells. Leuk Lymphoma. 2017 11; 58(11):2705-2716. PMID: 28394191.
      View in: PubMed
    8. Kebriaei P, Bassett R, Lyons G, Valdez B, Ledesma C, Rondon G, Oran B, Ciurea S, Alousi A, Popat U, Patel K, Ahmed S, Olson A, Bashir Q, Shah N, Jones R, Marin D, Rezvani K, Nieto Y, Khouri I, Qazilbash M, Hosing C, Shpall E, Champlin RE, Andersson BS. Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results. Biol Blood Marrow Transplant. 2017 Feb; 23(2):285-292. PMID: 27816651.
      View in: PubMed
    9. Valdez BC, Li Y, Murray D, Brammer JE, Liu Y, Hosing C, Nieto Y, Champlin RE, Andersson BS. Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy. Oncotarget. 2016 Sep 27; 7(39):63829-63838. PMID: 27564097.
      View in: PubMed
    10. Song G, Banov D, Bassani AS, Valdez BC. Evaluation of the Safety, Cell Migration, and Mucoadhesive Properties of a Mucoadhesive Polymer Blend in Human Oral Mucosa. AAPS PharmSciTech. 2017 Jul; 18(5):1617-1623. PMID: 27645471.
      View in: PubMed
    11. Alatrash G, Thall PF, Valdez BC, Fox PS, Ning J, Garber HR, Janbey S, Worth LL, Popat U, Hosing C, Alousi AM, Kebriaei P, Shpall EJ, Jones RB, de Lima M, Rondon G, Chen J, Champlin RE, Andersson BS. Long-Term Outcomes after Treatment with Clofarabine?±?Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant. 2016 10; 22(10):1792-1800. PMID: 27377901; PMCID: PMC5026955 [Available on 10/01/17].
    12. Valdez BC, Brammer JE, Li Y, Murray D, Teo EC, Liu Y, Hosing C, Nieto Y, Champlin RE, Andersson BS. Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells. Leuk Res. 2016 08; 47:100-8. PMID: 27294334.
      View in: PubMed
    13. Nieto Y, Valdez BC, Thall PF, Jones RB, Wei W, Myers A, Hosing C, Ahmed S, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Shah N, Bashir Q, Alousi A, Oki Y, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. Cancer. 2016 09 01; 122(17):2680-8. PMID: 27203405.
      View in: PubMed
    14. Teo EC, Valdez BC, Ji J, Li Y, Liu Y, Brammer JE, Hosing C, Nieto Y, Champlin RE, Andersson BS. Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells. Leuk Lymphoma. 2016 11; 57(11):2644-52. PMID: 26980288.
      View in: PubMed
    15. Ji J, Valdez BC, Li Y, Liu Y, Teo EC, Nieto Y, Champlin RE, Andersson BS. Cladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas: A preclinical study. Exp Hematol. 2016 06; 44(6):458-65. PMID: 26976752.
      View in: PubMed
    16. Nieto Y, Valdez BC, Thall PF, Ahmed S, Jones RB, Hosing C, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Alousi A, Shah N, Bashir Q, Liu Y, Oki Y, Hagemeister F, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. Biol Blood Marrow Transplant. 2015 Nov; 21(11):1914-20. PMID: 26071868; PMCID: PMC4781754 [Available on 11/01/16].
    17. Valdez BC, Li Y, Murray D, Ji J, Liu Y, Popat U, Champlin RE, Andersson BS. Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators. Exp Hematol. 2015 Jun; 43(6):448-61.e2. PMID: 25704054; PMCID: PMC4458397.
    18. Song G, Valdez BC, Li Y, Liu Y, Champlin RE, Andersson BS. Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells. Biol Blood Marrow Transplant. 2014 Nov; 20(11):1687-95. PMID: 25111583; PMCID: PMC5002996.
    19. Song G, Valdez BC, Li Y, Dominguez JR, Corn P, Champlin RE, Andersson BS. The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan. Leuk Lymphoma. 2014 Jul; 55(7):1625-34. PMID: 24144307.
      View in: PubMed
    20. Valdez BC, Wang G, Murray D, Nieto Y, Li Y, Shah J, Turturro F, Wang M, Weber DM, Champlin RE, Qazilbash MH, Andersson BS. Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implications. Exp Hematol. 2013 Aug; 41(8):719-30. PMID: 23648290; PMCID: PMC3769691.
    21. Nieto Y, Popat U, Anderlini P, Valdez B, Andersson B, Liu P, Hosing C, Shpall EJ, Alousi A, Kebriaei P, Qazilbash M, Parmar S, Bashir Q, Shah N, Khouri I, Rondon G, Champlin R, Jones RB. Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. Biol Blood Marrow Transplant. 2013 Mar; 19(3):410-7. PMID: 23128322; PMCID: PMC4077191.
    22. Valdez BC, Nieto Y, Murray D, Li Y, Wang G, Champlin RE, Andersson BS. Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines. Exp Hematol. 2012 Oct; 40(10):800-10. PMID: 22687754; PMCID: PMC3447105.
    23. Nieto Y, Thall P, Valdez B, Andersson B, Popat U, Anderlini P, Shpall EJ, Bassett R, Alousi A, Hosing C, Kebriaei P, Qazilbash M, Frazier E, Gulbis A, Chancoco C, Bashir Q, Ciurea S, Khouri I, Parmar S, Shah N, Worth L, Rondon G, Champlin R, Jones RB. High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies. Biol Blood Marrow Transplant. 2012 Nov; 18(11):1677-86. PMID: 22643322; PMCID: PMC4010147.
    24. Valdez BC, Murray D, Nieto Y, Li Y, Wang G, Champlin RE, Andersson BS. Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and suberoylanilide hydroxamic acid in lymphoma cell lines. Leuk Lymphoma. 2012 May; 53(5):973-81. PMID: 22023523.
      View in: PubMed
    25. Andersson BS, Valdez BC, de Lima M, Wang X, Thall PF, Worth LL, Popat U, Madden T, Hosing C, Alousi A, Rondon G, Kebriaei P, Shpall EJ, Jones RB, Champlin RE. Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Biol Blood Marrow Transplant. 2011 Jun; 17(6):893-900. PMID: 20946966; PMCID: PMC3760472.
    26. Valdez BC, Li Y, Murray D, Champlin RE, Andersson BS. The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling. Biochem Pharmacol. 2011 Jan 15; 81(2):222-32. PMID: 20933509; PMCID: PMC3006064.
    27. Valdez BC, Andersson BS. Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies. Environ Mol Mutagen. 2010 Jul; 51(6):659-68. PMID: 20577993; PMCID: PMC4346159.
    28. Valdez BC, Li Y, Murray D, Corn P, Champlin RE, Andersson BS. 5-Aza-2'-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis. Leuk Res. 2010 Mar; 34(3):364-72. PMID: 19732952; PMCID: PMC2823987.
    29. Valdez BC, Murray D, Ramdas L, de Lima M, Jones R, Kornblau S, Betancourt D, Li Y, Champlin RE, Andersson BS. Altered gene expression in busulfan-resistant human myeloid leukemia. Leuk Res. 2008 Nov; 32(11):1684-97. PMID: 18339423; PMCID: PMC2633244.
    30. Holmström TH, Mialon A, Kallio M, Nymalm Y, Mannermaa L, Holm T, Johansson H, Black E, Gillespie D, Salminen TA, Langel U, Valdez BC, Westermarck J. c-Jun supports ribosomal RNA processing and nucleolar localization of RNA helicase DDX21. J Biol Chem. 2008 Mar 14; 283(11):7046-53. PMID: 18180292.
      View in: PubMed
    31. Gonzales B, Yang H, Henning D, Valdez BC. Cloning and functional characterization of the Xenopus orthologue of the Treacher Collins syndrome (TCOF1) gene product. Gene. 2005 Oct 10; 359:73-80. PMID: 16125876.
      View in: PubMed
    32. Yang H, Henning D, Valdez BC. Functional interaction between RNA helicase II/Gu(alpha) and ribosomal protein L4. FEBS J. 2005 Aug; 272(15):3788-802. PMID: 16045751.
      View in: PubMed
    33. Gonzales B, Henning D, So RB, Dixon J, Dixon MJ, Valdez BC. The Treacher Collins syndrome (TCOF1) gene product is involved in pre-rRNA methylation. Hum Mol Genet. 2005 Jul 15; 14(14):2035-43. PMID: 15930015.
      View in: PubMed
    34. Valdez BC, Henning D, So RB, Dixon J, Dixon MJ. The Treacher Collins syndrome (TCOF1) gene product is involved in ribosomal DNA gene transcription by interacting with upstream binding factor. Proc Natl Acad Sci U S A. 2004 Jul 20; 101(29):10709-14. PMID: 15249688; PMCID: PMC489999.
    35. So RB, Gonzales B, Henning D, Dixon J, Dixon MJ, Valdez BC. Another face of the Treacher Collins syndrome (TCOF1) gene: identification of additional exons. Gene. 2004 Mar 17; 328:49-57. PMID: 15019983.
      View in: PubMed
    36. Henning D, So RB, Jin R, Lau LF, Valdez BC. Silencing of RNA helicase II/Gualpha inhibits mammalian ribosomal RNA production. J Biol Chem. 2003 Dec 26; 278(52):52307-14. PMID: 14559904.
      View in: PubMed
    37. Yang H, Zhou J, Ochs RL, Henning D, Jin R, Valdez BC. Down-regulation of RNA helicase II/Gu results in the depletion of 18 and 28 S rRNAs in Xenopus oocyte. J Biol Chem. 2003 Oct 03; 278(40):38847-59. PMID: 12851405.
      View in: PubMed
    38. Valdez BC, Perlaky L, Henning D. Expression, cellular localization, and enzymatic activities of RNA helicase II/Gu(beta). Exp Cell Res. 2002 Jun 10; 276(2):249-63. PMID: 12027455.
      View in: PubMed
    39. Coccia EM, Stellacci E, Orsatti R, Benedetti E, Giacomini E, Marziali G, Valdez BC, Battistini A. Protein inhibitor of activated signal transducer and activator of transcription (STAT)-1 (PIAS-1) regulates the IFN-gamma response in macrophage cell lines. Cell Signal. 2002 Jun; 14(6):537-45. PMID: 11897494.
      View in: PubMed
    40. Valdez BC, Yang H, Hong E, Sequitin AM. Genomic structure of newly identified paralogue of RNA helicase II/Gu: detection of pseudogenes and multiple alternatively spliced mRNAs. Gene. 2002 Feb 06; 284(1-2):53-61. PMID: 11891046.
      View in: PubMed
    41. Westermarck J, Weiss C, Saffrich R, Kast J, Musti AM, Wessely M, Ansorge W, Séraphin B, Wilm M, Valdez BC, Bohmann D. The DEXD/H-box RNA helicase RHII/Gu is a co-factor for c-Jun-activated transcription. EMBO J. 2002 Feb 01; 21(3):451-60. PMID: 11823437; PMCID: PMC125820.
    42. Valdez BC, Perlaky L. Drug-induced translocation of nucleolar proteins fused to green fluorescent protein. Methods Mol Biol. 2002; 183:151-61. PMID: 12136750.
      View in: PubMed
    43. Izumi RE, Valdez B, Banerjee R, Srivastava M, Dasgupta A. Nucleolin stimulates viral internal ribosome entry site-mediated translation. Virus Res. 2001 Jul; 76(1):17-29. PMID: 11376843.
      View in: PubMed
    44. Henning D, Valdez BC. Expression of p40/Epstein-Barr virus nuclear antigen 1 binding protein 2. Biochem Biophys Res Commun. 2001 May 04; 283(2):430-6. PMID: 11327720.
      View in: PubMed
    45. Zhu K, Henning D, Valdez B, Busch H. Human RNA helicase II/Gu gene: genomic organization and promoter analysis. Biochem Biophys Res Commun. 2001 Mar 09; 281(4):1006-11. PMID: 11237763.
      View in: PubMed
    46. Valdez BC. Structural domains involved in the RNA folding activity of RNA helicase II/Gu protein. Eur J Biochem. 2000 Nov; 267(21):6395-402. PMID: 11029582.
      View in: PubMed
    47. Valdez BC, Wang W. Mouse RNA helicase II/Gu: cDNA and genomic sequences, chromosomal localization, and regulation of expression. Genomics. 2000 Jun 01; 66(2):184-94. PMID: 10860663.
      View in: PubMed
    48. Garcia MC, Zhou J, Henning D, Arnett FC, Valdez BC. Unique epitopes in RNA helicase II/Gu protein recognized by serum from a watermelon stomach patient. Mol Immunol. 2000 May; 37(7):351-9. PMID: 11074253.
      View in: PubMed
    49. Zhu K, Henning D, Iwakuma T, Valdez BC, Busch H. Adriamycin inhibits human RH II/Gu RNA helicase activity by binding to its substrate. Biochem Biophys Res Commun. 1999 Dec 20; 266(2):361-5. PMID: 10600508.
      View in: PubMed
    50. Ou Y, Fritzler MJ, Valdez BC, Rattner JB. Mapping and characterization of the functional domains of the nucleolar protein RNA helicase II/Gu. Exp Cell Res. 1999 Mar 15; 247(2):389-98. PMID: 10066367.
      View in: PubMed
    51. Valdez BC, Perlaky L, Cai ZJ, Henning D, Busch H. Green fluorescent protein tag for studies of drug-induced translocation of nucleolar protein RH-II/Gu. Biotechniques. 1998 Jun; 24(6):1032-6. PMID: 9631199.
      View in: PubMed
    52. Gustafson WC, Taylor CW, Valdez BC, Henning D, Phippard A, Ren Y, Busch H, Durban E. Nucleolar protein p120 contains an arginine-rich domain that binds to ribosomal RNA. Biochem J. 1998 Apr 15; 331 ( Pt 2):387-93. PMID: 9531475; PMCID: PMC1219366.
    53. Valdez BC, Henning D, Perumal K, Busch H. RNA-unwinding and RNA-folding activities of RNA helicase II/Gu--two activities in separate domains of the same protein. Eur J Biochem. 1997 Dec 15; 250(3):800-7. PMID: 9461305.
      View in: PubMed
    54. Perlaky L, Valdez BC, Busch H. Effects of cytotoxic drugs on translocation of nucleolar RNA helicase RH-II/Gu. Exp Cell Res. 1997 Sep 15; 235(2):413-20. PMID: 9299166.
      View in: PubMed
    55. Arnett FC, Reveille JD, Valdez BC. Autoantibodies to a nucleolar RNA helicase protein in patients with connective tissue diseases. Arthritis Rheum. 1997 Aug; 40(8):1487-92. PMID: 9259430.
      View in: PubMed
    56. Zhu L, Perlaky L, Henning D, Valdez BC. Cloning and characterization of a new silver-stainable protein SSP29, a member of the LRR family. Biochem Mol Biol Int. 1997 Aug; 42(5):927-35. PMID: 9285060.
      View in: PubMed
    57. Valdez BC, Henning D, Perlaky L, Busch RK, Busch H. Cloning and characterization of Gu/RH-II binding protein. Biochem Biophys Res Commun. 1997 May 19; 234(2):335-40. PMID: 9177271.
      View in: PubMed
    58. Li YP, Busch RK, Valdez BC, Busch H. C23 interacts with B23, a putative nucleolar-localization-signal-binding protein. Eur J Biochem. 1996 Apr 01; 237(1):153-8. PMID: 8620867.
      View in: PubMed
    59. Valdez BC, Henning D, Busch RK, Woods K, Flores-Rozas H, Hurwitz J, Perlaky L, Busch H. A nucleolar RNA helicase recognized by autoimmune antibodies from a patient with watermelon stomach disease. Nucleic Acids Res. 1996 Apr 01; 24(7):1220-4. PMID: 8614622; PMCID: PMC145780.
    60. Ren Y, Busch R, Durban E, Taylor C, Gustafson WC, Valdez B, Li YP, Smetana K, Busch H. Overexpression of human nucleolar proteins in insect cells: characterization of nucleolar protein p120. Protein Expr Purif. 1996 Mar; 7(2):212-9. PMID: 8812864.
      View in: PubMed
    61. Valdez BC, Henning D, Busch RK, Srivastava M, Busch H. Immunodominant RNA recognition motifs of human nucleolin/C23. Mol Immunol. 1995 Nov; 32(16):1207-13. PMID: 8559145.
      View in: PubMed
    62. Weidner DA, Valdez BC, Henning D, Greenberg S, Busch H. Phosphorothioate oligonucleotides bind in a non sequence-specific manner to the nucleolar protein C23/nucleolin. FEBS Lett. 1995 Jun 12; 366(2-3):146-50. PMID: 7789533.
      View in: PubMed
    63. Valdez BC, Henning D, Le TV, Busch H. Specific aspartic acid-rich sequences are responsible for silver staining of nucleolar proteins. Biochem Biophys Res Commun. 1995 Feb 15; 207(2):485-91. PMID: 7532402.
      View in: PubMed
    64. Durban E, Valdez BC, Gustafson WC, Taylor CW, Cardellini E, Busch H. Functional domains of nucleolar phosphoprotein p120. Physiol Chem Phys Med NMR. 1995; 27(4):303-11. PMID: 8768786.
      View in: PubMed
    65. Busch RK, Perlaky L, Valdez BC, Henning D, Busch H. Apoptosis in human tumor cells following treatment with p120 antisense oligodeoxynucleotide ISIS 3466. Cancer Lett. 1994 Nov 11; 86(2):151-7. PMID: 7982202.
      View in: PubMed
    66. Valdez BC, Perlaky L, Henning D, Saijo Y, Chan PK, Busch H. Identification of the nuclear and nucleolar localization signals of the protein p120. Interaction with translocation protein B23. J Biol Chem. 1994 Sep 23; 269(38):23776-83. PMID: 8089149.
      View in: PubMed
    67. Saijo Y, Perlaky L, Valdez BC, Busch RK, Henning D, Zhang WW, Busch H. The effect of antisense p120 construct on p120 expression and cell proliferation in human breast cancer MCF-7 cells. Cancer Lett. 1993 Feb; 68(2-3):95-104. PMID: 8443798.
      View in: PubMed
    68. Saijo Y, Perlaky L, Valdez BC, Wang H, Henning D, Busch H. Cellular pharmacology of p120 antisense oligodeoxynucleotide phosphorothioate ISIS 3466. Oncol Res. 1993; 5(8):283-91. PMID: 8012060.
      View in: PubMed
    69. Valdez BC, Perlaky L, Saijo Y, Henning D, Zhu C, Busch RK, Zhang WW, Busch H. A region of antisense RNA from human p120 cDNA with high homology to mouse p120 cDNA inhibits NIH 3T3 proliferation. Cancer Res. 1992 Oct 15; 52(20):5681-6. PMID: 1394192.
      View in: PubMed
    70. Perlaky L, Valdez BC, Busch RK, Larson RG, Jhiang SM, Zhang WW, Brattain M, Busch H. Increased growth of NIH/3T3 cells by transfection with human p120 complementary DNA and inhibition by a p120 antisense construct. Cancer Res. 1992 Jan 15; 52(2):428-36. PMID: 1728415.
      View in: PubMed
    71. Valdez BC, Busch RK, Busch H. Phosphorylation of the human cell proliferation-associated nucleolar protein p120. Biochem Biophys Res Commun. 1990 Nov 30; 173(1):423-30. PMID: 2256932.
      View in: PubMed
    72. Valdez BC, Busch RK, Larson RG, Busch H. Identification of an epitope region of the human proliferation-associated nucleolar antigen P120. Cancer Res. 1990 May 01; 50(9):2704-7. PMID: 1691680.
      View in: PubMed
    73. Valdez BC, Chen Z, Sosa MG, Younathan ES, Chang SH. Human 6-phosphofructo-1-kinase gene has an additional intron upstream of start codon. Gene. 1989 Mar 15; 76(1):167-9. PMID: 2526044.
      View in: PubMed
    74. Valdez BC, French BA, Younathan ES, Chang SH. Site-directed mutagenesis in Bacillus stearothermophilus fructose-6-phosphate 1-kinase. Mutation at the substrate-binding site affects allosteric behavior. J Biol Chem. 1989 Jan 05; 264(1):131-5. PMID: 2521215.
      View in: PubMed
    75. Fonagy A, Henning D, Jhiang S, Haidar M, Busch RK, Larson R, Valdez B, Busch H. Cloning of the cDNA and sequence of the human proliferating-cell nucleolar protein P120. Cancer Commun. 1989; 1(4):243-51. PMID: 2576976.
      View in: PubMed
    76. Valdez BC, Chang SH, Younathan ES. Site-directed mutagenesis at the regulatory site of fructose 6-phosphate-1-kinase from Bacillus stearothermophilus. Biochem Biophys Res Commun. 1988 Oct 14; 156(1):537-42. PMID: 2972287.
      View in: PubMed
    77. French BA, Valdez BC, Younathan ES, Chang SH. High-level expression of Bacillus stearothermophilus 6-phosphofructo-1-kinase in Escherichia coli. Gene. 1987; 59(2-3):279-83. PMID: 2963782.
      View in: PubMed
    78. Reciprocal regulation of glycolytic and pentose phosphate pathways by fructose 1,6-bisphosphate. Federation Proceedings. 44.
    79. Silver (agNOR) staining of nucleolar transcription factor UBF requires adjacent aspartic acid residues. Journal of Histotechnology. 21:13-18.
    80. Biology of Blood and Marrow Transplantation. 22:1792-1800.
    81. Pretransplant conditioning with fludarabine and IV busulfan, reduced toxicity and increased safety without compromising antitumor efficacy and overall treatment effect?. Bone Marrow Transplantation.
    82. Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells. Leukemia and Lymphoma. 1-9.
    83. Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy. Oncotarget. 7:63829-63838.
    84. Pharmacologic Basis for High-dose Chemotherapy. 211-224.
    85. Nucleolar protein p!20 binds to rRNA. FASEB Journal. 10.
    86. Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells. Leukemia Research. 47:100-108.
    87. Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. Biology of Blood and Marrow Transplantation. 21:1914-1920.
    88. Evaluation of the Safety, Cell Migration, and Mucoadhesive Properties of a Mucoadhesive Polymer Blend in Human Oral Mucosa. AAPS PharmSciTech. 1-7.
    89. A nucleolar RNA heucase recognized by antibodies from a patient with watermelon stomach disease. FASEB Journal. 10.
    90. Synergistic cytotoxicity of gemcitabine, clofarabine and edelfosine in lymphoma cell lines. Blood Cancer Journal. 4.
    91. Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation. 23:285-292.
    92. Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients. Bone Marrow Transplantation.
    93. Cladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas. Experimental Hematology.
    94. The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan. Leukemia and Lymphoma. 55:1625-1634.
    VALDEZ's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description